These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11812256)

  • 1. Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia.
    Ito C
    Curr Pharm Des; 2002; 8(2):147-53. PubMed ID: 11812256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43.
    Vukosavic S; Ruzdijic S; Veskov R; Rakic L; Kanazir S
    Neurosci Res; 2001 Jun; 40(2):133-40. PubMed ID: 11377751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis.
    Steinpreis RE
    Behav Brain Res; 1996 Jan; 74(1-2):45-55. PubMed ID: 8851914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphetamine psychosis: behavioral and biochemical aspects.
    Angrist B; Sathananthan G; Wilk S; Gershon S
    J Psychiatr Res; 1974; 11():13-23. PubMed ID: 4461784
    [No Abstract]   [Full Text] [Related]  

  • 5. DARK Classics in Chemical Neuroscience: Phencyclidine (PCP).
    Bertron JL; Seto M; Lindsley CW
    ACS Chem Neurosci; 2018 Oct; 9(10):2459-2474. PubMed ID: 29953199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippocampal CA1 region shows differential regulation of gene expression in mice displaying extremes in behavioral sensitization to amphetamine: relevance for psychosis susceptibility?
    Datson NA; Speksnijder N; de Jong IE; Steenbergen PJ; Vielsted Christensen K; Potempa K; Torleif Pedersen J; Egebjerg J; Kallunki P; Nielsen EB; de Kloet ER; Didriksen M
    Psychopharmacology (Berl); 2011 Oct; 217(4):525-38. PubMed ID: 21537941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release.
    Balla A; Sershen H; Serra M; Koneru R; Javitt DC
    Neuropsychopharmacology; 2003 Jan; 28(1):34-44. PubMed ID: 12496938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.
    Ballmaier M; Bortolato M; Rizzetti C; Zoli M; Gessa G; Heinz A; Spano P
    Neuropsychopharmacology; 2007 Oct; 32(10):2098-107. PubMed ID: 17299506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.
    Snyder SH
    Am J Psychiatry; 1973 Jan; 130(1):61-7. PubMed ID: 4345465
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Therapeutic Conference: dopaminergic/serotonergic actions of phencyclidine as a model for schizophreniform psychosis.
    Gabbert JF; Giannini AJ
    Am J Ther; 1997 Apr; 4(4):159-63. PubMed ID: 10423606
    [No Abstract]   [Full Text] [Related]  

  • 11. Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine.
    Ko F; Tallerico T; Seeman P
    Synapse; 2006 Aug; 60(2):141-51. PubMed ID: 16715494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization.
    Yui K; Goto K; Ikemoto S; Ishiguro T; Angrist B; Duncan GE; Sheitman BB; Lieberman JA; Bracha SH; Ali SF
    Mol Psychiatry; 1999 Nov; 4(6):512-23. PubMed ID: 10578232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
    Javitt DC
    Hillside J Clin Psychiatry; 1987; 9(1):12-35. PubMed ID: 2820854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia.
    Rajagopal L; Kwon S; Huang M; Michael E; Bhat L; Cantillon M; Meltzer HY
    Behav Brain Res; 2017 Aug; 332():180-199. PubMed ID: 28373127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release.
    Balla A; Koneru R; Smiley J; Sershen H; Javitt DC
    Neuropsychopharmacology; 2001 Aug; 25(2):157-64. PubMed ID: 11425499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment.
    Marksteiner J; Weiss U; Weis C; Laslop A; Fischer-Colbrie R; Humpel C; Feldon J; Fleischhacker WW
    Neuroscience; 2001; 104(2):325-33. PubMed ID: 11377837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine.
    Sams-Dodd F
    Neuropsychopharmacology; 1998 Apr; 18(4):293-304. PubMed ID: 9509497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catecholamines in the brain as mediators of amphetamine psychosis.
    Snyder SH
    Arch Gen Psychiatry; 1972 Aug; 27(2):169-79. PubMed ID: 4339577
    [No Abstract]   [Full Text] [Related]  

  • 19. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study.
    Rosse RB; Collins JP; Fay-McCarthy M; Alim TN; Wyatt RJ; Deutsch SI
    Clin Neuropharmacol; 1994 Aug; 17(4):359-69. PubMed ID: 9316684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of NMDA receptors and the phencyclidine model of schizophrenia.
    Thornberg SA; Saklad SR
    Pharmacotherapy; 1996; 16(1):82-93. PubMed ID: 8700797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.